Dynamic FoxO transcription factors
In International Journal of Molecular Sciences, 2006
... Antibodies against p70S6K (Thr389), p4E-BP1 (Thr37/46), pAkt (Thr308), pTSC2 (Thr1462), pAMPK-α (Thr172), LKB1 and pACC (Ser79) were purchased from Cell Signaling Technology, Inc ... Role of Nrf2 in the regulation of CD36 and stress protein expression in murine macrophages: activation by oxidatively modified LDL and 4-hydroxynonenalmore suppliers
In Arthritis Research & Therapy, 2003
... for thrombin, PAR1, PAR3, PAR4, c-Src, PKCδ, and Nrf2, and siRNA against PAR1, PAR3, and PAR4 were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA) ...
Retrospective multicentre study investigating the role of targeted next-generation sequencing of selected cancer genes in mucinous adenocarcinoma of the lung.
Torino, Italy. In J Thorac Oncol, Feb 2016
The majority of mutations clustered in the MAP-AKT kinase (KRAS, PIK3CA, STK11, PTEN, AKT1, HRAS, BRAF) and the p53/DNA repair (TP53, CDKN2A, ATM, RB1) pathways.
Metformin and pancreatic cancer: Is there a role?
Boston, United States. In Cancer Chemother Pharmacol, Feb 2016
Metformin influences various cellular pathways, including activation of the LKB1/AMPK pathway, inhibition of cell division, promotion of apoptosis and autophagy, down-regulation of circulating insulin, and activation of the immune system.
Control of YAP/TAZ Activity by Metabolic and Nutrient-Sensing Pathways.
Padova, Italy. In Trends Cell Biol, Jan 2016
The activity of the YAP/TAZ transcriptional coactivators, downstream transducers of the Hippo cascade and powerful pro-oncogenic factors, was recently found to be regulated by metabolic pathways, such as aerobic glycolysis and mevalonate synthesis, and by the nutrient-sensing LKB1-AMPK and TSC-mTOR pathways.
Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations.
More papers using
Guangzhou, China. In J Clin Oncol, Aug 2015
RESULTS: In addition to confirming mutations in known cancer-associated genes (TP53, KRAS, PIK3CA, MET, NOTCH, STK11, and RB1), several novel mutations in additional genes, including RASA1, CDH4, CDH7, LAMB4, SCAF1, and LMTK2, were identified and validated.